Subtype selective substrates for histone deacetylases

被引:110
|
作者
Heltweg, B
Dequiedt, F
Marshall, BL
Branch, C
Yoshida, M
Nishino, N
Verdin, E
Jung, M
机构
[1] Univ Munster, Dept Pharmaceut & Med Chem, D-48149 Munster, Germany
[2] FUSAGx, Mol & Cellular Biol Unit, B-5030 Gembloux, Belgium
[3] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA
[4] RIKEN, Chem Genet Lab, Wako, Saitama 3510198, Japan
[5] Kyushu Inst Technol, Dept Appl Chem, Tabata Ku, Kitakyushu, Fukuoka 8048550, Japan
关键词
D O I
10.1021/jm0497592
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To probe the steric requirements for deacylation, we synthesized lysine-derived small molecule substrates and examined structure -reactivity relationships with various histone deacetylases. Rat liver, human HeLa, and human recombinant class I and II histone deacetylases (HDACs) as well as human recombinant NAD(+)-dependent SIRT1 (class III enzyme) were used in these studies. A benzyloxycarbonyl substituent on the alpha-amino group yielded the highest conversion rates. Replacing the epsilon-acetyl group with larger lipophilic acyl substituents led to a pronounced decrease in conversion by class I and II enzymes; the class III enzyme displayed a greater tolerance. Incubations with recombinant FLAG-tagged human HDACs 1, 3, and 6 showed a distinct subtype selectivity among small molecule substrates. The subtype selectivity of HDAC inhibitors could be predicted with these substrates and an easily obtainable mixture of HDAC subtypes.
引用
收藏
页码:5235 / 5243
页数:9
相关论文
共 50 条
  • [1] Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
    Yao, Ya-Li
    Yang, Wen-Ming
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011,
  • [2] Selective inhibition of mutant histone deacetylases.
    Hedglin, M
    Ulrich, SM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U492 - U492
  • [3] Histone deacetylases: Purification of the enzymes, substrates, and assay conditions
    Rezai-Zadeh, N
    Tsai, SC
    Wen, YD
    Yao, YL
    Yang, WM
    Seto, E
    CHROMATIN AND CHROMATIN REMODELING ENZYMES, PT C, 2004, 377 : 167 - 179
  • [4] Innovative Strategies for Selective Inhibition of Histone Deacetylases
    Maolanon, Alex R.
    Madsen, Andreas S.
    Olsen, Christian A.
    CELL CHEMICAL BIOLOGY, 2016, 23 (07): : 759 - 768
  • [5] Non-histone substrates of histone deacetylases as potential therapeutic targets in epilepsy
    Kumar, Sonali
    Attrish, Diksha
    Srivastava, Arpna
    Banerjee, Jyotirmoy
    Tripathi, Manjari
    Chandra, P. Sarat
    Dixit, Aparna Banerjee
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (01) : 75 - 85
  • [6] Computational Studies on the Histone Deacetylases and the Design of Selective Histone Deacetylase Inhibitors
    Wang, Difei
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (03) : 241 - 256
  • [7] Histone deacetylases
    Horn, David
    DRUG TARGETS IN KINETOPLASTID PARASITES, 2008, 625 : 81 - 86
  • [8] Histone deacetylases
    Marks, PA
    Miller, T
    Richon, VM
    CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) : 344 - 351
  • [9] The teratogen valproic acid is a selective inhibitor of a subset of histone deacetylases
    Zhu, P
    Krämer, OH
    Heinzel, T
    Göttlicher, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R148 - R148
  • [10] Selective regulation of class I and class II histone deacetylases expression by inhibitors of histone deacetylases in cultured mouse neural cells
    Ajamian, F
    Salminen, A
    Reeben, M
    NEUROSCIENCE LETTERS, 2004, 365 (01) : 64 - 68